Entecavir as a first-line treatment for hepatitis B virus reactivation following polychemotherapy for chronic lymphocytic leukemia and invasive ductal carcinoma: a report of two cases and review of the literature


TURKER K., ALBAYRAK M., OKSUZOGLU B., BALCI E. , OGAN M. C. , ISKENDER G., et al.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, cilt.27, ss.39-45, 2015 (SCI İndekslerine Giren Dergi)

  • Cilt numarası: 27 Konu: 1
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1097/meg.0000000000000115
  • Dergi Adı: EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
  • Sayfa Sayısı: ss.39-45

Özet

Objective Hepatitis B reactivation has been reported in chronic carriers of hepatitis B [hepatitis B surface antigen (HBsAg)] or in patients with prior hepatitis B virus (HBV) infection who are HBsAg-negative and have antibodies against hepatitis B core antigen (anti-HBc) with or without antibodies to HBsAg (anti-HBs). Lamivudine has been the first and commonly used nucleoside analog to inhibit HBV replication; however, prolonged therapy has been associated with an increased risk for drug-resistant mutations and mortality rates. Entecavir, a deoxyguanosine analog, offers several advantages over lamivudine for the treatment of HBV reactivation following chemotherapy while exhibiting more potent antiviral activity and a lower resistance rate.